OCUP: Ocuphire Pharma, Inc. Stock

by  •  • Comments Off on OCUP: Ocuphire Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 45.66
Enterprise Value ($M) -4.84
Book Value ($M) 49.91
Book Value / Share 2.01
Price / Book 0.91
NCAV ($M) 49.91
NCAV / Share 2.01
Price / NCAV 0.91

Profitability (mra)
Return on Invested Capital (ROIC) -0.20
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.24

Liquidity (mrq)
Quick Ratio 13.35
Current Ratio 13.35

Balance Sheet (mrq) ($M)
Current Assets 53.95
Assets 53.95
Liabilities 4.04
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 19.05
Operating Income -10.56
Net Income -9.99
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.11
Cash from Investing 0.00
Cash from Financing 8.98

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURS
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-15 46,937 195,013 24.07
2024-04-12 174,290 51,627 337.59
2024-04-11 35,404 47,219 74.98
2024-04-10 37,260 23,000 162.00

(click for more detail)

Similar Companies
NVCT – Nuvectis Pharma, Inc. OCEA – Ocean Biomedical, Inc.
OCGN – Ocugen, Inc. OCX – OncoCyte Corporation
OKYO – OKYO Pharma Limited


Financial data and stock pages provided by
Fintel.io